

New Metabolites from the Marine Sponge Scopalina hapalia Collected in Mayotte Lagoon

Charifat Saïd Hassane, Gaëtan Herbette, Elnur Garayev, Fathi Mabrouki, Patricia Clerc, Nicole de Voogd, Stephane Greff, Ioannis Trougakos, Jamal Ouazzani, Mireille Fouillaud, et al.

▶ To cite this version:

Charifat Saïd Hassane, Gaëtan Herbette, Elnur Garayev, Fathi Mabrouki, Patricia Clerc, et al.. New Metabolites from the Marine Sponge Scopalina hapalia Collected in Mayotte Lagoon. Marine drugs, 2022, 20 (3), pp.186. 10.3390/md20030186. hal-03681424

HAL Id: hal-03681424

https://hal.science/hal-03681424

Submitted on 20 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.







Article

New Metabolites from the Marine Sponge *Scopalina hapalia* Collected in Mayotte Lagoon

Charifat Saïd Hassane ¹, Gaëtan Herbette ², Elnur Garayev ³, Fathi Mabrouki ³, Patricia Clerc ¹, Nicole J. de Voogd ^{4,5}, Stephane Greff ³, Ioannis P. Trougakos ⁶, Jamal Ouazzani ⁷, Mireille Fouillaud ¹, Laurent Dufossé ¹, Béatrice Baghdikian ³, Evelyne Ollivier ³ and Anne Gauvin-Bialecki ^{1,*}

- Laboratoire de Chimie et de Biotechnologie des Produits Naturels, Faculté des Sciences et Technologies, Université de La Réunion, 15 Avenue René Cassin, CS 92003, CEDEX 09, 97744 Saint-Denis, France; charifat.saidhassane@gmail.com (C.S.H.); patricia.clerc@univ-reunion.fr (P.C.); mireille.fouillaud@univ-reunion.fr (M.F.); laurent.dufosse@univ-reunion.fr (L.D.)
- ² CNRS, Centrale Marseille, FSCM, Spectropole, Aix Marseille Université, Campus de St Jérôme-Service 511, 13397 Marseille, France; gaetan.herbette@univ-amu.fr
- ONRS 7263, IRD 237, IMBE, Aix Marseille Université, Avignon Université, 13331 Marseille, France; elnur.garayev@univ-amu.fr (E.G.); fathi.mabrouki@univ-amu.fr (F.M.); stephane.greff@imbe.fr (S.G.); beatrice.baghdikian@univ-amu.fr (B.B.); evelyne.ollivier@univ-amu.fr (E.O.)
- ⁴ Naturalis Biodiversity Center, Darwinweg 2, 2333 CR Leiden, The Netherlands; nicole.devoogd@naturalis.nl
- ⁵ Institute of Environmental Sciences, Leiden University, Einsteinweg 2, 2333 CC Leiden, The Netherlands
- Department of Cell Biology and Biophysics, Faculty of Biology, National and Kapodistrian University of Athens, 15784 Athens, Greece; itrougakos@biol.uoa.gr
- Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Saclay, 1, Av. de la Terrasse, 91198 Gif-sur-Yvette, France; jamal.ouazzani@cnrs.fr
- * Correspondence: anne.bialecki@univ-reunion.fr

Abstract: The biological screening of 44 marine sponge extracts for the research of bioactive molecules, with potential application in the treatment of age-related diseases (cancer and Alzheimer's disease) and skin aging, resulted in the selection of *Scopalina hapalia* extract for chemical study. As no reports of secondary metabolites of *S. hapalia* were found in the literature, we undertook this research to further extend current knowledge of *Scopalina* chemistry. The investigation of this species led to the discovery of four new compounds: two butenolides sinularone J (1) and sinularone K (2), one phospholipid 1-*O*-octadecyl-2-pentanoyl-*sn*-glycero-3-phosphocholine (3) and one lysophospholipid 1-*O*-(3-methoxy-tetradecanoyl)-*sn*-glycero-3-phosphocholine (4) alongside with known lysophospholipids (5 and 6), alkylglycerols (7–10), epidioxysterols (11 and 12) and diketopiperazines (13 and 14). The structure elucidation of the new metabolites (1–4) was determined by detailed spectroscopic analysis, including 1D and 2D NMR as well as mass spectrometry. Molecular networking was also explored to complement classical investigation and unravel the chemical classes within this species. GNPS analysis provided further information on potential metabolites with additional bioactive natural compounds predicted.

Keywords: Scopalina hapalia; butenolides; lipids; diketopiperazines; molecular networking; bromotyrosine



Citation: Saïd Hassane, C.; Herbette, G.; Garayev, E.; Mabrouki, F.; Clerc, P.; de Voogd, N.J.; Greff, S.; Trougakos, I.P.; Ouazzani, J.; Fouillaud, M.; et al. New Metabolites from the Marine Sponge *Scopalina hapalia* Collected in Mayotte Lagoon. *Mar. Drugs* 2022, 20, 186. https://doi.org/10.3390/md20030186

Academic Editor: Rosa Maria Vitale

Received: 14 February 2022 Accepted: 25 February 2022 Published: 2 March 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Marine sponges are known as an extensive source of novel natural products with a wide variety of biological activities [1]. As a hotspot of biodiversity, the Comoros Archipelago, situated off the southeastern coast of Africa, in the Mozambique channel, is poorly explored for natural products chemistry [2]. Hence, the archipelago represents a great potential for the discovery of original biologically active metabolites [3,4]. In the course of our research aimed at the discovery of bioactive metabolites with potential application in the treatment of age-related diseases and skin aging such as anti-CDK7, anti-tyrosinase or sirtuin 1 activators substances, 44 marine sponges were collected from

Mar. Drugs 2022, 20, 186 2 of 17

the lagoon of Mayotte and evaluated. This screening effort revealed 19 marine sponges potentially producing anti-aging metabolites. These bioactive marine sponges include highly studied genera such as Haliclona [5] and Jaspis, as well as less studied ones like Scopalina and Svenzea. Amongst this last category, the Scopalina hapalia (Order Scopalinida) [6] extract exhibited significant inhibitory activities against the protein kinase FynB and elastase, respectively, involved in neurodegenerative diseases [7,8] and skin aging [9]. Therefore, it was selected for further chemical investigation. This extract gained special attention mainly as, at this moment, only six metabolites were reported from a specimen of S. ruetzleri (formerly known as Ulosa ruetzleri) collected in Harrington Sound, Bermuda [10]. The first compounds reported were an unusual lipid 17Z-tetracosenyl 1-glycerol ether along with batyl alcohol and 4-(4-hydroxyphenyl)-3-buten-2-one [10]. However, the last compound is suspected to be an artifact derived from the aldol condensation of the extraction solvent acetone with p-hydroxybenzaldehyde [10]. In 1986, the new compound 4-hydroxy-5-(indole-3-yl)-5-oxo-pentan-2-one with plant regulatory activity was isolated [11]. The last two novel compounds reported were a phosphorylated hydantoin, ulosantoin, and a structurally related compound, dimethyl N2-creatininylphosphate [12]. While ulosantoin exhibited significant insecticidal property, dimethyl N2-creatininylphosphate showed no activity in the insecticidal screening [12]. More recently, organic extracts or fractions of S. ruetzleri collected near Brazilian and Colombian coasts exhibited anti-proliferative effects on human breast cancer cells [13], antifungal effects against Candida albicans [14], antioxidant effect [15] as well as cytotoxic activities against human glioma and neuroblastoma cell lines [15]. An ethanolic extract of S. hapalia collected from the reefs of Zanzibar also demonstrated antibacterial and concentration-dependent cytotoxic activities [16] opening up interesting perspectives for this understudied species. The species Scopalina hapalia is largely distributed in the southwestern region of the Indian Ocean (Zanzibar, Mayotte). It was also reported in Australia, Papua New Guinea [17] and Singapore [18].

In this study, we report the isolation of two new 2,3-dimethyl butenolide derivatives (1 and 2), one new phospholipid (3), one new lysophospholipid (4) alongside with known lysophospholipids (5 and 6), alkylglycerols (7–10), epidioxysterols (11 and 12) and diketopiperazines (13 and 14) (Figure 1). While the extract showed inhibition activity in the Fyn kinase and elastase bioassays, indicating the presence of bioactive compounds, most of the isolated compounds were obtained in insufficient amounts for biological testing. Contrary to our expectations, the few tested compounds (6, 8, 9) did not show significant biological activity. This paper reports the structural elucidation of the new compounds. Further, in an attempt to thoroughly assess the molecular potential of this less studied genus, we use a GNPS molecular networking approach. This approach revealed several chemical classes, among which some were isolated.

Mar. Drugs 2022, 20, 186 3 of 17

Figure 1. Chemical structures of new (1–4) and known (5–14) metabolites isolated from *Scopalina hapalia*.

Mar. Drugs **2022**, 20, 186 4 of 17

2. Results and Discussion

2.1. Chemical Investigation

Sponge specimens were extracted with CH_2Cl_2/CH_3OH (1:1) and the resulting extracts were evaluated against molecular targets involved in age-related diseases and skin aging. The CH_2CL_2/CH_3OH extract of *Scopalina hapalia* was found to inhibit 48% and 44% of the elastase activity, respectively, at the concentration of both 10 $\mu g/mL$ and 1 $\mu g/mL$. The same extract also inhibited the activity of the protein kinase FynB in a concentration dependent manner at 111 $\mu g/mL$, 11.1 $\mu g/mL$, and 1.1 $\mu g/mL$. Consequently, the CH_2CL_2/CH_3OH (1:1) extract was fractionated by MPLC, however, none of the obtained fractions exhibited anti-aging activities. Despite the loss of bioactivity, the chemical investigation was pursued. The CH_2CL_2/CH_3OH extract was, first, subjected to partition between cyclohexane and CH_3OH . The CH_3OH -soluble portion was chromatographed over C-18 silica gel, followed by semipreparative C-18 silica HPLC purification, yielding compounds (1, 12–14). In a second phase, the whole CH_2CL_2/CH_3OH extract was also fractionated by MPLC over silica gel. Fractions of interest were further purified by either analytical or semipreparative C-18 silica HPLC to give metabolites (2–11).

The known compounds were identified by comparing their spectroscopic and/or spectrometric data with those reported in the literature (for structures and NMR data, see Supplementary Material). Compounds **5** and **6** were, respectively, identified as the known lysophospholipids 1-*O*-octadecyl-*sn*-glycero-3-phosphocholine [19] and 1-palmitoyl-*sn*-glycero-3-phosphocholine [20]. Compounds **7** to **10** correspond to known monoalkyl glycerol ethers previously isolated from marine sponges: 1-*O*-hexadecylglycerol (chimyl alcohol **7**) [21], 1-*O*-octadecylglycerol (batyl alcohol **8**) [21], 3-nonadecyloxy-1,2-propanediol (glycerol 1-nonadecyl ether **9**) [22] and 3-icosoxypropane-1,2-diol (glycerol 1-eicosyl ether **10**) [22]. Compounds **11** and **12** were determined, respectively, as a mixture of 5α ,8 α -epidioxy-24(R/S)-hydroperoxystigmasta-6,28-dien-3 β -ol [23] and a mixture of 5α ,8 α -epidioxy-24(R/S)-stigmasta-6,22E-dien-3 β -ol [24]. These two epidioxysterols were previously isolated from marine sponges *Lendenfeldia chondrodes* [23] and *Thalysias juniperina* [24]. The last two known compounds identified were diketopiperazines cyclo(Val-Leu) (**13**) and cyclo(Val-Phe) (**14**) [25]. These two compounds have previously been isolated from marine microorganisms *Streptomyces fungicidicus* and *Paecilomyces marquandii* [26,27].

Compound 1 was isolated as a yellow oil. High-resolution mass spectrometry (HRMS) analysis revealed a sodium adduct ion at m/z 349.1985 [M + Na]⁺ consistent with molecular formula $C_{18}H_{30}O_5$ and incorporating four unsaturations. It provided a negative specific rotation $[a]_{589}^{25} - 40$ (c 0.024, CH₃OH). Analysis of the ¹H NMR and HSQC data (Table 1) indicated that **1** contained two olefinic methyl singlets H-16 ($\delta_{\rm H}$ 1.84) and H-17 ($\delta_{\rm H}$ 1.90), one oxygenated methyl protons H-18 ($\delta_{\rm H}$ 3.07), two methylene protons near heteroatom H-5 ($\delta_{\rm H}$ 1.73, 1.95) and H-14 ($\delta_{\rm H}$ 2.15) and eight methylene protons ($\delta_{\rm H}$ 1.13–1.59). A comprehensive analysis of the 13 C NMR revealed two olefinic carbons C-2 (δ_C 128.4) and C-3 (δ_C 158.4), one ketone C-1 (δ_C 173.8), one carboxylic acid carbonyl C-15 (δ_C 183.0), one methoxy carbon C-18 (δ_C 50.5) and one acetal C-4 (δ_C 111.9). HMBC correlations from H-16 to C-1, C-2, C-3 and from H-17 to C-2, C-3 and C-4 were observed (Figure 2). These correlations along with the additional HMBC correlation between H-18 and C-4 disclosed a substitued α , β -unsaturated 2,3-dimethyl- γ -lactone moiety, similar to that of the known butenolide 13-(2-hydroxy-3,4-dimethyl-5-oxo-2,5-dihydrofuran-2-yl) tridecanoic acid methyl ester and sinularones [28,29]. In the COSY spectrum, H-5, H-12, and H-13 showed correlations, respectively, to H-6, H-13, and H-14. In combination with the HMBC correlations between H-5 and C-4, C-6, C-7 in one hand, as well as H-14 and C-12, C-13, C-15 in the other hand, a carboxylic acid side chain from C-5 to C-15 was confirmed. In regard to the absolute configuration of carbon C-4, some of the known butenolides with α,β -unsaturated 2,3dimethyl- γ -lactone moiety were reported to have R configuration at their stereogenic center and to show negative optical rotation, such as caulerpalide B [30]. Therefore, as compound **1** exhibited a negative optical rotation $(a]_{589}^{25} - 40$, we tentatively assumed C-4 to be 4R

Mar. Drugs **2022**, 20, 186 5 of 17

configuration. Consequently, compound 1 was identified as sinularone J, a new butenolide, analogue to sinularones [29].

No.	1		
	δ _C , Type	δ _H (J in Hz)	HMBC, $H \rightarrow C$
1	173.8, OC=O		
2	128.4, =CH		
3	158.4, =CH		
4	111.9, C		
5	36.5, CH ₂	1.95 (m) 1.73 (m)	C-4, C-6, C-7
6	23.8, CH ₂	1.24 (m) 1.13 (m)	
7–12	30.8–30.5, CH ₂	1.33-1.27 (m)	
13	27.7, CH ₂	1.59 (brqt 7.4)	C-12, C-14, C-15

2.15 (brt7.8)

1.84 (q, 1.2)

1.90 (q, 1.2)

3.07(s)


C-12, C-13, C-15

C-1, C-2, C-3

C-2, C-3, C-4

C-4

Table 1. NMR Spectroscopic data for **1** in CD₃OD at 600 (1 H) and 150 (13 C) MHz.



39.1, CH₂

183.0, C 8.2, CH₃

10.9, CH₃

50.5, CH₃

14 15

16 17

18

Figure 2. Key COSY (bold bonds) and HMBC (blue arrows) correlations for compound 1.

Compound **2** was isolated as a colorless oil. High-resolution mass spectrometry (HRMS) analysis revealed a sodium adduct ion at m/z 433.2921 [M + Na]⁺ consistent with molecular formula $C_{24}H_{42}O_5$ and incorporating four unsaturations. It provided a negative specific rotation $[a]_{589}^{25} - 75$ (c 0.021, CH₃OH). The NMR data of compound **2** (Table 2) were similar to those of **1** with the exception of the carboxylic acid side chain length. This information was supported by the molecular weight of **2** (m/z 433.2921) [M + Na]⁺, which is 84 amu more than that of **1** (m/z 349.1985) [M + Na]⁺ consistent with a difference of six methylenes. HMBC interactions from H-5 to C-4, C-6, C-7 and from H-20 to C-18, C-19, C-21 helped to establish the attachment of the carboxylic acid side chain made of 16 methylenes to the α , β -unsaturated 2,3-dimethyl- γ -lactone moiety (Figure 3). In regard to the absolute configuration of carbon C-4, we supposed C-4 to be 4R configuration as well. Therefore, compound **2** was identified as sinularone K, a structural analog of **1**.

Mar. Drugs **2022**, 20, 186 6 of 17

No.	2		
	δ _C ^a , Type	δ _H (J in Hz)	HMBC, $H \rightarrow C$
1	173.8, OC=O		
2	128.4, =CH		
3	158.4, =CH		
4	111.9, C		
5	36.6, CH ₂	1.96 (m) 1.73 (m)	C-4, C-6, C-7
6	23.9, CH ₂	1.24 (m) 1.14 (m)	
7–18	31.0–30.6, CH ₂	1.33-1.27 (m)	
19	27.8, CH ₂	1.59 (qt, 7.5)	
20	39.2, CH ₂	2.16 (t, 7.5)	C-18, C-19, C-21
21	182.9, C		
22	8.3, CH ₃	1.83 (q, 1.1)	C-1, C-2, C-3
23	10.9, CH ₃	1.90 (q, 1.1)	C-2, C-3, C-4
24	50.5, CH ₃	3.07 (s)	C-4

Table 2. NMR Spectroscopic data for **2** in CD₃OD at 600 (¹H) and 150 (¹³C) MHz.

 $[\]overline{}^{a}$ δ_{C} were determined from HSQC and HMBC experiments.




Figure 3. HMBC (blue arrows) correlations for compound 2.

Compound 3 was isolated as an amorphous powder. Its molecular formula was established as $C_{31}H_{63}NO_9P^+$ based on a protonated molecule ion at m/z 624.4235 [M + H]⁺ consistent with molecular formula $C_{31}H_{62}NO_9P$, incorporating three unsaturations. HRMS/MS readily allowed the recognition of a phosphatidylcholine skeleton. MS/MS fragmentations decompose compound 3 to produce ions at m/z 510.4 [M + H]⁺ consistent with molecular formula $C_{26}H_{56}NO_6P$ (1-O-octadecyl-sn-glycero-3-phosphocholine), m/z 184.1 [M + H]⁺ consistent with molecular formula $C_5H_{14}NO_4P$ (protonated phosphocholine ion), m/z125.0 [M + H]⁺ consistent with molecular formula $C_2H_5O_4P$ (protonated phosphate), m/z86.1 [M + H]⁺ consistent with molecular formula $C_5H_{11}N$ (phosphocholine head) that are diagnostic fragments for glycerophosphatidylcholine species [31]. Analysis of ¹H NMR, HSQC and HMBC (Table 3) showed oxygenated methylene and methine proton signals C-1 ($\delta_{\rm H}$ 3.59, 3.61; $\delta_{\rm C}$ 70.2), C-2 ($\delta_{\rm H}$ 5.17; $\delta_{\rm C}$ 73.2), C-3 ($\delta_{\rm H}$ 3.97, 4.03; $\delta_{\rm C}$ 65.5) belonging to a glycerol unit, methylene proton signals attached to heteroatoms C-1" ($\delta_{\rm H}$ 4.27; $\delta_{\rm C}$ 60.5), C-2" ($\delta_{\rm H}$ 3.65; $\delta_{\rm C}$ 67.4) as well as a singlet signal integrated to nine methyl protons corresponding to three N-methyl groups (δ_H 3.23; δ_C 54.7) indicated the presence of choline. The presence of a linear alkyl chain was also shown by methylene proton signals (δ_H 1.25-1.54; $\delta_{\rm C}$ 23.8-30.8). One methylene is attached to a heteroatom C-1'($\delta_{\rm H}$ 3.43, 3.48; $\delta_{\rm C}$ 72.7) and another one is a terminal methyl group C-18 ($\delta_{\rm H}$ 0.90; $\delta_{\rm C}$ 14.5). The connectivity between the glycerol unit at C-1 and the alkyl chain portion through the ether bond was determined from HMBC correlations between H-1 and C-2, C-3, C-1' and between H-1' and C-1 (Figure 4). Characteristic coupling between phosphorus and relevant protons (H-3 and H-1") were observed with ¹H-³¹P HMBC correlations confirming the connectivity

Mar. Drugs **2022**, 20, 186 7 of 17

between the choline and the glycerol (C-3) units through phosphate. HMBC correlations from H-2 to C-1"' and from H-2"' to C-1"' indicated the presence of an ester-linked alkyl chain at C-2. The molecular formula of the residue at C-2 ($C_5H_6O_3$) was deduced from HRMS/MS. The 1H NMR spectrum, along with HSQC and HMBC experiments (Table 3), showed one ester carbonyl C-1"" (δ_C 174.4), one carboxylic acid carbonyl C-5"" (δ_C 178.7) and three methylene carbons. Moreover, the COSY cross-peaks between H-2"", H-3"" and H-4"", in association with HMBC interactions of these protons to the carbonyl carbon C-5" allowed to secure the carboxylic acid function. Therefore, the structure of 3 was determined as 1-O-octadecyl-2-pentanoyl-sn-glycero-3-phosphocholine.

Table 3. NMR Spectrosco	oic data for 3 in CD ₃ OD at 600	(^{1}H) and 150 ($^{13}C)$ MHz.

No.	3		
	δ _C ^a , Type	δ _H (J in Hz)	HMBC, $H \rightarrow C$
1	70.2, CH ₂	3.59 (1H, dd 10.9, 5.9) 3.61 (1H, dd 10.9, 4.7)	C-2, C-3, C-1'
2	73.2, CH	5.17 (1H, m)	C-1, C-3, C-1'''
3	65.5, CH ₂	3.97 (1H, dt 11.1, 6.1 ^b) 4.03 (1H, ddd 11.1, 5.7, 4.2 ^b)	C-1, C-2
1′	72.7, CH ₂	3.43 (1H, dt 9.3, 6.6) 3.48 (1H, dt 9.3, 6.7)	C-1, C-2', C-3'
2′	30.8, CH ₂	1.54 (2H, brqt 6.8)	
3′	27.6, CH ₂	1.35–1.25 (30H, ov ^c)	
4'-15'	30.7, CH ₂	1.33–1.27 (m)	
16′	33.2, CH ₂	1.59 (qt, 7.5)	
17′	23.8, CH ₂	2.16 (t, 7.5)	
18'	14.5, CH ₃	0.90 (3H, t 7.1)	C-16', C-17'
1''	60.5 (d 5.4) ^b , CH ₂	4.27 (2H, m ^b)	
2''	67.4 (m) ^b , CH ₂	3.65 (2H, m)	C-1", N+(CH ₃) ₃
N ⁺ (CH ₃) ₃	54.7 (m) b, CH ₃	3.23 (brs)	C-2", N+(CH ₃) ₃
1′′′	174.4, C		
2'''	34.6, CH ₂	2.42 (2H, brt 7.5)	C-1''', C-4'''
3′′′	22.1, CH ₂	1.90 (2H, brqt 7.5)	C-1''', C-5'''
4′′′	35.9, CH ₂	2.31 (2H, brt 7.3)	C-2''', C-5'''
5′′′	178.7, C		

 $^{^{\}overline{a}}$ δ_{C} were determined from HSQC and HMBC experiments; b 1 H $-^{31}$ P couplings; c overlapping signals.




Figure 4. Key COSY (bold bonds) and HMBC (blue arrows) correlations for compound 3.

Compound 4 was isolated as an amorphous powder. Its molecular formula was established as $C_{23}H_{49}NO_8P^+$ based on a protonated molecule ion at m/z 498.3188 [M + H]⁺ (calcd for $C_{23}H_{49}NO_8P^+$ 498.3190), incorporating 2 unsaturations. MS/MS fragmentations of compound 4 produce several diagnostic fragments ions of glycerophosphocholine [31],

Mar. Drugs **2022**, 20, 186 8 of 17

amongst which ions at m/z 258.1 [M + H]⁺ consistent with molecular formula C₈H₂₀NO₆P (protonated glycerophosphocholine moiety)), m/z 184.1 [M + H]⁺ consistent with molecular formula $C_5H_{14}NO_4P$ (protonated phosphocholine ion), m/z 125.0 [M + H]⁺ consistent with molecular formula $C_2H_5O_4P$ (protonated phosphate), m/z 104.1 [M + H]⁺ and m/z 86.1 $[M + H]^+$ consistent with molecular formula $C_5H_{13}NO^+$ and $C_5H_{11}N$ (phosphocholine head group fragments). Further information on the structure of the phospholipid was deduced from ¹H NMR, COSY and HSQC data (Table 4). Analysis of the ¹H NMR spectrum of compound 4, along with HSQC experiment, showed the resonances of methylene and methine protons belonging to a glycerol moiety acylated at C-1 (δ_H 4.19, 4.13; δ_C 66.0), nonacylated at C-2 ($\delta_{\rm H}$ 3.98; $\delta_{\rm C}$ 69.4) and phosphorylated at C-3 ($\delta_{\rm H}$ 3.90; $\delta_{\rm C}$ 67.4). The shift in the oxygenated methylene protons signals observed at δ_H 3.59 and 3.61 (H-1) in 3 to δ_H 4.19 and 4.13 indicated the presence of an ester linkage instead of an ether linkage. The phosphocholine moiety was revealed by methylene proton signal attached to heteroatoms C-1" $(\delta_{\rm H} 4.29; \delta_{\rm C} 60.1), C-2''$ $(\delta_{\rm H} 3.65; \delta_{\rm C} 67.0)$ and a singlet signal integrated to nine methyl protons corresponding to three N-methyl groups (δ_H 3.23; δ_C 54.3). The presence of a linear alkyl chain was also observed in the ¹H NMR spectrum along with characteristic proton and carbon signals arising from oxymethyl group (δ_H 3.34 and δ_C 56.9). Due to the low quantities obtained for 4, the HMBC experiment could not be conducted. However, COSY correlations from H-2' to H-3' and HSQC correlation between H-3' (δ_H 3.66) and C-3' (δ_C 78.8) showed that the oxymethyl group is located at C-3' (Figure 5). Therefore, the structure of 4 was determined as 1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine.

Table 4. NMR Spectroscopic data for 4 in CD₃OD at 600 (¹H) and 150 (¹³C) MHz.

No. ^a	4		
	δ _C ^b , Type	δ _H (J in Hz)	COSY, $H \rightarrow H$
1	66.0, CH ₂	4.19 (dd, 10.9; 4.7) 4.13 (dd, 10.9; 5.9)	
2	69.4, CH	3.98 (m)	
3	67.4, CH ₂	3.90 (m)	
1'	no	-	
2′	39.9, CH ₂	2.54 (dd, 15.3; 7.3) 2.51 (dd, 15.3; 5.6)	3′
3'	78.8, CH	3.66 (m)	2′
4'	34.5, CH ₂	1.53 (m)	
5'-12'	33.2, CH ₂	1.35–1.25 (ov ^c)	14'
13'	23.4, CH ₂	2.16 (t, 7.5)	
14'	14.1, CH ₂	0.90 (t, 7.1)	13′
OCH ₃	56.9, CH ₃	3.34 (s)	
1''	60.1, CH ₂	4.29 (m)	2''
2''	67.0, CH ₂	3.65 (m)	1''
N ⁺ (CH ₃) ₃	54.3, CH ₃	3.23 (s)	

^a All assignments are based on ¹H NMR and 2D NMR measurements (COSY, HSQC); ^b δ_C were determined from HSQC experiment; ^c overlapping signals.

Mar. Drugs **2022**, 20, 186 9 of 17

Figure 5. Key COSY (bold bonds) correlation for compound 4.

2.2. Molecular Networking

In an effort to fully capture the chemical space of this Scopalina hapalia specimen, molecular networking was used to complement the traditional chemical investigation. The former approach provides a method to rapidly assess the diversity and the chemical relatedness of metabolites based on similarities in MS/MS parent ion fragmentation patterns [32]. Fractions were prepared after removal of the major nonpolar lipids from *Scopalina* hapalia crude extract and analyzed by UHPLC-HRMS/MS in positive mode. Obtained MS/MS data were then used to generate molecular networks using the online plateform Global Natural Products Social Molecular Networking (GNPS). Molecular networks of the fractions (Figure 6A) revealed the presence of clusters related to different chemical classes (see Supplementary Material): polar lipids (lysophospholipids and fatty acids derivatives); amino acids derivatives (peptides and diketopiperazines); alkaloids (purines and β-carbolines) and terpenoids; reflecting at some points the results from the isolation procedure. The dereplication process highlighted three specific ion clusters (MN1–MN3). Interestingly, the isolated compounds 1 and 2 were detected in cluster MN1 (Figure 6B). Therefore, they were used as "seed molecules" in the analysis. Although no library hit was found for this cluster through the GNPS workflow, the dictionary of natural products database provided fruitful information for manual dereplication based on the molecular formulae proposed from HRMS and MS/MS fragmentation patterns. In that respect, two other 2,3-dimethyl-4-methoxybutenolides and two β -hydroxybutenolides (tetronic acid derivatives) were detected in cluster MN1. This partial annotation suggests that cluster MN1 aggregate different types of butenolide along with potential new butenolide analogues. The small number as well as the low amount of butenolide derivatives yielded by traditional detection and isolation techniques point to the probability that these compounds could be produced by the microbial symbionts of *Scopalina hapalia*. Typically associated with Gram-positive bacteria, butenolides are signaling molecules known to regulate morphological development and secondary metabolism, especially antibiotic production in the genus Streptomyces [33]. Commonly produced in low amounts (their biological concentration range from micro- to nano-molar), their isolation has proven difficult [34]. Furthermore, the analysis of the MS spectra from nodes belonging to clusters MN2 and MN3 revealed isotopic patterns that pointed toward brominated compounds (Figure 6C). Manual dereplication of cluster MN2 and MN3 based on the molecular formula matched, respectively, with six bromotyrosine alkaloids and two bromotyramine derivatives. Bromotyrosine-derived alkaloids are bioactive metabolites (antiviral, antibacterial, anticancer) typically found in sponges belonging to the Verongida order [35]. Given that this finding is based on the analysis of one specimen, additional work on Scopalina species would help to unambiguously demonstrate that these compounds can be detected in sponges belonging to the genus Scopalina. However, bromotyrosine derivatives have also been found in phylogenetically unrelated organisms like Tetractinellida sponges [36], ascidians [37,38] and the marine obligate bacterium Pseudovibrio denitrificans isolated from the marine sponge Arenosclera brasiliensis (order Haplosclerida) [39]. The occurrence of bromotyrosine across taxonomically distant group of organisms suggests that these metabolites might be produced by symbiont microorganisms. Hence, to prove the microbial origin of these metabolites (butenolides and bromotyrosines), future work based on molecular networking dereplication of the culturable microbial symbiont extracts need to be performed.

Mar. Drugs **2022**, 20, 186




Figure 6. (**A**) Molecular Network constructed using MS/MS data from fractions of *Scopalina hapalia*, obtained after the removal of non-polar lipids of organic crude extract, with a cosine similarity cutoff of 0.7. Edge thickness corresponds to relative cosine score similarity between nodes. Annotated clusters are enlarged. (**B**) Cluster MN1 based on compounds **1** and **2** (octagonal nodes) related to butenolide derivatives. (**C**) Cluster MN2 and MN3 related to bromotyrosine metabolites.

Mar. Drugs **2022**, 20, 186 11 of 17

To sum up, in our preliminary investigation of marine sponge crude extracts for their anti-aging activities, the organic extract from S. hapalia inhibited the activity of the elastase and the protein kinase FynB. However, the screening of the fractions obtained subsequently did not show any biological activity. This lack of follow-up activity suggest that the strong inhibition observed for the crude extract might be the result of synergistic effect from metabolites. It is relevant to note that in spite of the multiple biological activities (antiproliferative, cytotoxic, antioxidant, antibacterial and antifungal) exhibited by either S. ruetzleri or S. hapalia crude extracts or fractions [13–16], there is only six metabolites reported from S. ruetzleri. Therefore, the fractionation of S. hapalia was pursued, independently of bioactivity, in order to gain a better understanding of its chemical composition. This work led to the isolation of fourteen metabolites, including two new butenolides derivatives sinularones J and K (1 and 2), one new phospholipid 1-Ooctadecyl-2-pentanoyl-sn-glycero-3-phosphocholine (3) and one new lysophospholipid 1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine (4). The absolute configuration at C-4 of the new butenolides remains to be confirmed as we supposed it to be of R form. The compounds reported here, with the exception of 8, represent new additions to the literature of this poorly studied genus. However, given the too low amounts obtained during isolation, most of the compounds (1-4, 6 and 7, 10-14) could not be evaluated against the selected molecular targets (elastase, tyrosinase, CDK7, FynB and proteasome). In particular, the new compounds were present in concentrations too low to be efficiently purified. To address these shortcomings, a collection of a new specimen of *Scopalina hapalina* is being considered. Compounds 5, 8 and 9 were primary screened against CDK7, FynB and proteasome at three different concentrations (33 µg/mL, 3.3 µg/mL, 0.33 µg/mL) to identify inhibitors of these molecular targets. Compound 5 showed a weak inhibitory activity to proteasome, however only at the lowest concentration tested suggesting an eventual artifact. Consequently, compounds 5, 8 and 9 were not further investigated for IC50 experimentation. These compounds were also evaluated for their activities in an elastase and tyrosinase bioassays at the concentrations of 1 and 10 µg/mL. None of these compounds displayed significant inhibition of elastase and tyrosinase activities. Compound 5 exhibited the highest inhibition by 7% at 1 μg/mL and 11% at 10 μg/mL for elastase bioassay; this activity is much lower compared to the active extract (inhibition by 44% at 1 μg/mL and 48% at 10 μg/mL in a cell-based elastase bioassay). Since these compounds were not significantly active, cell-based bioassays were not performed. As the current study was unable to identify bioactive compounds, an important question remains to be resolved for future studies, namely which metabolites are responsible for S. hapalia anti-elastase and anti-fynB activities, or are there synergistic effects of several compounds leading to the observed bioactivities. However, according to the literature, compounds 5, 8, 9, 12, 13 and 14 are already known to possess activities such as cytotoxicity, antifouling, antibacterial, immunomodulatory and quorum sensing sensors [23,27,40-46]. These bioactive compounds with antimicrobial and cytotoxic activities might explain the biological activities displayed by the Scopalina specimens. In addition, applying molecular networking for dereplication has proven to be useful. Based on the molecular network, several diketopiperazines and butenolides analogues were dereplicated. The most striking result to emerge from our data is the presence of bromotyrosine compounds in the fractions of *S. hapalia*. Additional work on the isolation of these predicted metabolites would be of great interest in order to confirm their presence. In conclusion, our results are encouraging and should be validated by further research on other *Scopalina* species.

3. Materials and Methods

3.1. General Experimental Procedure

NMR spectra were recorded on a Bruker Avance III-600 spectrometer (600 MHz for 1 H and 150 MHz for 13 C) equipped with de TCI Cryoprobe in 2.0 mm o.d. capillary tube at 300 K. Chemical shifts were referenced using the corresponding solvent signals ($\delta_{\rm H}$ 3.31

Mar. Drugs **2022**, 20, 186 12 of 17

and δ_C 49.00 for CD₃OD 99.96%-d). The spectra were processed using 1D and 2D NMR TopSpin software.

High Resolution MS spectra of isolated compounds were measured using a Waters SYNAPT G2 HDMS TOF mass spectrometer with an electrospray ionization (ESI) source. Samples were solubilized in 300 μ L of CH₃OH and then diluted to 1/100 in a solution of 3 mM ammonium acetate in CH₃OH.

Optical rotations were measured on an MCP 200 Anton Paar modular circular polarimeter at 25 $^{\circ}$ C (CH₃OH, c in g/100 mL) in a 10 \times 5 mm i.d., 0.2 mL sample cell at 589 nm (Na D-line).

MPLC separations were carried out on Buchi Sepacore flash systems C-605/C-615/C-660 and glass column (230 \times 15 mm) packed with Macherey-Nagel MN Kieselgel silica gel (60–200 µm) or Acros Organic C-18 reverse phase. Analytical and semi-preparative HPLC were performed using either a Thermo Scientific Dionex Ultimate 3000 system equipped with a diode array detector (DAD) and a Corona detector or an Agilent 1200 system with DAD for analytical HPLC and a Gilson PLC 2020 with DAD for semipreparative HPLC. Analytical work was conducted using a Phenomenex Gemini C_{18} reversed-phased column (150 \times 4.6 mm, 3 µm) and semi-preparative HPLC was undertaken using a Phenomenex Gemini C_{18} reversed-phased column (250 \times 10 mm, 5 µm). UHPLC was carried out on Dionex Ultimate 3000 system connected to Bruker Impact II TOF mass spectrometer equipped with a Zorbax Eclipse Plus C_{18} (100 \times 2.1 mm, 1.8 µm, Agilent) column. All solvents were analytical or HPLC grade and were used without further purification. The sponge was lyophilized with a CRYOTEC Cosmos 20K freeze dryer.

3.2. Animal Material

Scopalina hapalia (order Scopalinida, family Scopalinidae) was collected in May 2013 by scuba diving at the depths of 2–10 m around the south east coasts of Mayotte (Kani tip, GPS (12°57.624′ S; 45°04.697′ E). The sponge sample was levered off with a thin-bladed knife to prevent damage, transferred to a plastic bag and kept at −20 °C before being transported to the laboratory. The taxonomic identification was performed by Nicole de Voogd and a voucher specimen was preserved in 80% ethanol and is deposited at Naturalis Biodiversity Center, Leiden the Netherlands as RMNH POR.8376. Scopalina hapalia was originally described with some reservation as Hymeniacidon hapalia by Hooper et al., (1997) from Australia, however was transferred to the genus Scopalina by Alvarez and Hooper in 2010. The species is orange in coloration with a prominent spiky surface and its consistency is very fragile, soft and slimy. The skeleton is composed of ill-defined spongin fibres cored by spicules and obscured by granular material. The spicules are slightly curved styles with rough and uneven endings with a dimension of 338–462–566 \times 5–8–10 μ m (as min-mean-max). We compared our species with the related species Scopalina australiensis and Scopalina rubra. The present species is very similar to Scopalina australiensis from the Great Barrier Reef, however in addition to styles the spicules have oxeote modifications and are thinner and slightly larger in dimension. Another similar species is Scopalina rubra (originally described as *Ulosa rubra*) from Madagascar by Vacelet and Vasseur (1971), which is very close to our collection site. A type slide was examined (MNHN DJV32) and although the spicule dimensions are very similar to S. hapalia, namely $330-550 \times 10-15 \mu m$, the skeleton is very different. The skeleton is composed of regular thick multispicular spongin tracks and is not obscured by granular material. The outer morphology appears also very different, not as soft as our specimen with clear large oscules after preservation.

3.3. Extraction and Isolation Procedure

The lyophilized sponge (74.3 g, dry weight) was extracted overnight, once with Water to remove excess salt and three times using CH₃OH/CH₂Cl₂ (1:1, v:v). The organic solvent was filtered and evaporated under reduced pressure to yield an orange/brown residue (7.82 g). A mass of 6.57 g of the extract was then partitioned between cyclohexane and aqueous CH₃OH (10% water) (1:1, v:v). The methanolic layers were evap-

Mar. Drugs **2022**, 20, 186

orated affording 2.76 g of a crude residue. A mass of 2.24 g of this extract was subjected to fractionation by medium pressure liquid chromatography MPLC. The sample was absorbed on silica gel C_{18} (<five times the mass of the sample), dry-loaded onto a sintered glass silica C_{18} a column (230 \times 15 mm), and eluted using a gradient solvent system of H₂O and CH₃OH (10 mL·min⁻¹). Eighteen fractions of 45 mL each were collected. Fraction 7 (18.4 mg) was separated using reverse-phase C₁₈ semipreparative HPLC, eluting with a gradient elution from 10% to 78% H₂O/CH₃CN (+0.1% formic acid F.A) over 55 min (3 mL·min⁻¹), yielding 1 (0.4 mg), 13 (0.1 mg) and 14 (0.3 mg). Fraction 16 (13.6 mg) was subjected to reverse-phase C₁₈ semipreparative HPLC using a gradient elution from 78% to 97% H₂O/CH₃CN (+0.1% F.A) (3 mL⋅min⁻¹) yielding 12 (0.2 mg). Another portion of the crude extract CH₃OH/CH₂Cl₂ (1:1, v:v) was fractionated by MPLC on silica gel using a combination of solvent with increasing polarity (2-methylpentane, EtOAc, CH₂Cl₂, CH₃OH) yielding eleven fractions (15 mL⋅min⁻¹) (2methylpentane/EtOAc 95:5; 2-methylpentane/EtOAc 90:10; 2-methylpentane/EtOAc 85:15; 2-methylpentane/EtOAc 80:20; 2-methylpentane/EtOAc 70:30; 2-methylpentane/EtOAc 50:50; EtOAc 100%; CH_2CL_2 100%, $3 \times CH_3OH$ 100%). Fractions 4 and 5 eluted at 20 and 30 % EtOAc were combined to give a major fraction F4-F5 (~73.1 mg). An aliquot of this fraction (59.1 mg) was further separated using open column chromatography over silica gel, using isohexane with increasing proportions of EtOAc as eluent. Fractions eluted at 50% EtOAc were combined (13.7 mg) and subjected to reverse-phase C_{18} analytical HPLC. Elution was conducted with a linear gradient from 65% to 100% H₂O/CH₃CN (+0.1% F.A) over 30 min and held at 100% CH₃CN (+0.1% F.A) for 20 min (0.7 mL·min⁻¹) yielding 2 (0.1 mg) and 11 (0.1 mg). An aliquot of F10-F11 (68.7 mg), eluted at 100% CH₃OH, was separated using reverse-phase C₁₈ semipreparative HPLC with a linear gradient from 5% to $100\% H_2O/CH_3CN (+0.1\% F.A)$ over 38 min and maintained at $100\% CH_3CN (+0.1\% F.A)$ F.A) for 10 min (4.5 mL·min⁻¹) yielding 3 (0.1 mg), 4 (0.1 mg), 5 (0.1 mg), 6 (0.1 mg). An aliquot of fraction 6 (28.7 mg), eluted at 50% EtOAc, was separated via reverse-phase C₁₈ semipreparative HPLC, eluting with an isocratic solvent system of H₂O:CH₃CN (+ 0.1% F.A) 10:90 (v:v) held for 45 min followed by 100% CH₃CN + 0.1% F.A maintained for 10 min $(4.5 \text{ mL} \cdot \text{min}^{-1})$, yielding 7 (0.8 mg), 8 (4.0 mg), 9 (1.5 mg) and 10 (0.3 mg).

3.4. Compound Characterization

Sinularone J (1): yellow oil; $[a]_{589}^{25} - 40$ (c 0.024, CH₃OH); 1 H and 13 C NMR, see Table 1; HRMS m/z 349.1985 [M + Na]⁺ (calcd for C₁₈H₃₀O₅Na⁺ 349.1985).

Sinularone K (2): colorless oil; $[a]_{589}^{25} - 75$ (c 0.021, CH₃OH); ¹H and ¹³C NMR, see Table 2; HRMS m/z 433.2924 [M + Na]⁺ (calcd for C₂₄H₄₂O₅Na⁺ 433.2924).

1-*O*-octadecyl-2-pentanoyl-*sn*-glycero-3-phosphocholine (3): amorphous powder; 1 H and 13 C NMR, see Table 3; ESI-MS m/z 624.4 [M + H]⁺ (6), 510.4 (1), 184.1 (100), 125.0 (3), 86.1 (4); HRMS m/z 624.4235 [M + H]⁺ (calcd for $C_{31}H_{63}NO_{9}P^{+}$ 624.4235).

1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine (4): amorphous powder; 1 H and 13 C NMR, see Table 4; ESI-MS m/z 498.3 [M + H]⁺ (40), 258.1 (4), 184.1 (100), 125.0 (4), 104.1 (13), 86.1 (5); HRMS m/z 498.3188 [M + H]⁺ (calcd for $C_{23}H_{49}NO_{8}P^{+}$ 498.3190).

3.5. Elastase and Tyrosinase Activity Assays

For the in vitro screening of the elastase enzyme activity, we used elastase from porcine pancreas (PPE) type IV and N-succinyl-Ala-Ala-p-nitroanilide as substrate; the assay was conducted as described before in Said Hassane et al. (2020) [47]. Elastatinal was used as positive control.

To evaluate the inhibitory potency of the extract and compounds against tyrosinase, the oxidation of L-DOPA to dopachrome was determined against mushroom tyrosinase (92 U/mL), as previously described [47]. Kojic acid was used as positive control.

In both assays, experiments were performed in duplicates and negative control contained PBS and the substrate. Blanks contained all the assay components except the enzyme.

Mar. Drugs **2022**, 20, 186

3.6. CDK7 Inhibition Assay

CDK7 activity was evaluated using CDK7 (Crelux construct CZY3, PC11452). The inhibitory potency of the compounds against CDK7 was determined by using the ADP-Glo Kinase Assay (Promega, Madison, WI, USA) and CDKtide as substrate. The assay was carried out according to the method previously described [5]. An IC $_{50}$ of 203 nM was determined for staurosporine using XLfit. It can generally be stated that the assay worked properly, as the control compound staurosporine, which was run in parallel to the assay, provided the expected results.

3.7. Fyn Kinase Inhibition Assay

FynB activity was evaluated using FynB wt (Crelux construct CTX4, PC09815-1). The inhibitory potency of the compounds against FynB was determined by using the ADP-Glo Kinase Assay (Promega) and Fyn kinase substrate (Enzo Life Sciences, P215). The assay was carried out according the method previously described [5]. An IC $_{50}$ of 0.191 μ M was determined for staurosporine using XLfit. In general, it can be stated that the assay worked properly, as the control compound staurosporine, which was run in parallel to the assay, exhibited good results.

3.8. Proteasome Inhibition Assay

Proteasome activity was evaluated using yeast proteasome (TUM Groll group) in its storage buffer: 20 mM Tris/HCl pH 7.5. The inhibitory potency of the isolated compounds to yeast proteasome was assessed by using the Fluorescence Intensity Assay and Suc-Leu-Leu-Val-Tyr-AMC as substrate (Enzo Life Sciences, BML-P802-0005). The assay was carried out according to the method previously described [5]. An IC $_{50}$ of 0.0366 nM was calculated for ONX-0914 using XLfit. It can generally be stated that the Fluorescence Intensity Assay worked properly, as the control compound ONX-0914, which was run in parallel to the assay, showed the expected results.

3.9. Global Natural Product Social Molecular Networking

A molecular network was created using the online workflow (https://ccms-ucsd. github.io/GNPSDocumentation/, accessed on 23 June 2020) on the GNPS website (http: //gnps.ucsd.edu, accessed on 23 June 2020) [32]. The data was filtered by removing all MS/MS fragment ions within ± 17 Da of the precursor m/z. MS/MS spectra were window filtered by choosing only the top six fragment ions in the ± 50 Da window throughout the spectrum. The precursor ion mass tolerance was set to 0.02 Da and an MS/MS fragment ion tolerance of 0.02 Da. A network was then created where edges were filtered to have a cosine score above 0.7 and more than six matched peaks. Furthermore, edges between two nodes were kept in the network if and only if each of the nodes appeared in each other's respective top 10 most similar nodes. Finally, the maximum size of a molecular family was set to 100, and the lowest scoring edges were removed from molecular families until the molecular family size was below this threshold. The spectra in the network were then searched against GNPS' spectral libraries. The library spectra were filtered in the same manner as the input data. All matches kept between network spectra and library spectra were required to have a score above 0.7 and at least six matched peaks. Mass spectrometry data of all H₂O/CH₃OH Scopalina hapalia fractions used in this study were added to the Public Massive datasets in GNPS (Massive ID MSV000085622).

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/md20030186/s1, Figure S1. HRMS-ESI+ spectrum of sinularone J (1), Figure S2. ¹H NMR spectrum of sinularone J (1) (600 MHz, in CD₃OD), Figure S3. ¹³C NMR spectrum of sinularone J (1) (150 MHz, in CD₃OD), Figure S4. 1H-1H COSY spectrum of sinularone J (1) (600 MHz, in CD₃OD), Figure S5. HSQC spectrum of sinularone J (1) (600 MHz, in CD₃OD), Figure S6. HMBC spectrum of sinularone J (1) (600 MHz, in CD₃OD), Figure S7. HRMS-ESI+ spectrum of sinularone K (2), Figure S8. 1H NMR spectrum of sinularone K (2) (600 MHz, in CD₃OD), Figure S9. 1H-1H COSY

Mar. Drugs **2022**, 20, 186 15 of 17

spectrum of sinularone K (2) (600 MHz, in CD₃OD), Figure S10. HSQC spectrum of sinularone K (2) (600 MHz, in CD₃OD), Figure S11. HMBC spectrum of sinularone K (2) (600 MHz, in CD₃OD), Figure S12. HRMS-ESI-TOF spectrum of 1-O-octadecyl-2-pentanoyl-sn-glycero-3-phosphocholine (3), Figure S13. 1H NMR spectrum of 1-O-octadecyl-2-pentanoyl-sn-glycero-3-phosphocholine (3) (600 MHz, in CD₃OD), Figure S14. 1H-1H COSY spectrum of 1-O-octadecyl-2-pentanoyl-sn-glycero-3phosphocholine (3) (600 MHz, in CD₃OD), Figure S15. HSQC spectrum of 1-O-octadecyl-2-pentanoylsn-glycero-3-phosphocholine (3) (600 MHz, in CD₃OD), Figure S16. HMBC spectrum of 1-O-octadecyl-2-pentanoyl-sn-glycero-3-phosphocholine (3) (600 MHz, in CD₃OD), Figure S17. HRMS ESI-TOF spectrum of 1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine (4), Figure S18. 1H NMR spectrum of 1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine (4) (600 MHz, in CD₃OD), Figure S19. 1H-1H COSY spectrum of 1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine (4) (600 MHz, in CD₃OD), Figure S20. HSQC spectrum of 1-O-(3-methoxy-tetradecanoyl)-sn-glycero-3-phosphocholine (4) (600 MHz, in CD₃OD), Figure S21. HRMS ESI-TOF of 1-O-octadecyl-sn-glycero-3-phosphocholine (5), Figure S22. 1H NMR spectrum of compound 1-O-octadecyl-sn-glycero-3phosphocholine (5) (600 MHz, in CD₃OD), Figure S23. HRMS-ESI⁺ spectrum of compound 1palmitoyl-sn-glycero-3-phosphocholine (6), Figure S24. 1H NMR spectrum of compound 1-palmitoylsn-glycero-3-phosphocholine (6) (600 MHz, in CD₃OD), Figure S25. HRMS-ESI⁺ spectrum of com $pound\ 1-O-hexadecylglycerol\ (7),\ Figure\ S26.\ 1H\ NMR\ spectrum\ of\ compound\ 1-O-hexadecylglycerol\ (8)$ (7) (600 MHz, in CD₃OD), Figure S27. HRMS-ESI⁺ spectrumof compound 1-O-octadecylglycerol (8), Figure S28. ¹H NMR spectrum of compound 1-O-octadecylglycerol (8) (600 MHz, in CD₃OD), Figure S29. HRMS-ESI⁺ spectrum of compound 3-nonadecyloxy-1,2-propanediol (9), Figure S30. ¹H NMR spectrum of compound 3-nonadecyloxy-1,2-propanediol (9) (600 MHz, in CD₃OD), Figure S31. HRMS-ESI⁺ spectrum of compound 3-icosoxypropane-1,2-diol (10), Figure S32. ¹H NMR spectrum of compound 3-icosoxypropane-1,2-diol (10) (600 MHz, in CD₃OD), Figure S33. HRMS-ESI⁺ spectrum of compound 5α , 8α -epidioxy-24(R/S)-hydroperoxystigmasta-6,28-dien-3 β -ol (11), Figure S34. ¹H NMR spectrum of compound 5α , 8α -epidioxy-24(R/S)-hydroperoxystigmasta-6,28-dien- 3β -ol (11) (600 MHz, in CD₃OD), Figure S35. HRMS-ESI+ spectrum of compound 5α , 8α -epidioxy-24(R/S)stigmasta-6,22*E*-dien-3 β -ol (12), Figure S36. ¹H NMR spectrum of compound 5α , 8α -epidioxy-24(R/S)stigmasta-6,22E-dien-3β-ol (12) (600 MHz, in CD₃OD), Figure S37. ¹H NMR spectrum of compound cyclo(Val-Leu) (13) (600 MHz, in CD₃OD), Figure S38. ¹H NMR spectrum of compound cyclo(Val-Phe) (14) (600 MHz, in CD₃OD), Figure S39. Dereplication of *Scopalina hapalia* fractions using LC-MS/MS molecular networking, Figure S40. Dereplication of Scopalina hapalia fractions using LC-MS/MS molecular networking.

Author Contributions: Conceptualization, funding acquisition and project administration, A.G.-B. and J.O.; bioassays (elastase and tyrosinase) methodology and validation, I.P.T.; formal analysis, C.S.H. and S.G., chemical investigation (extraction, isolation, and structural identification of the compounds), C.S.H., G.H., E.G., F.M. and P.C.; resources, A.G.-B. (sponge collections) and N.J.d.V. (sponge identification); writing—original draft preparation, C.S.H.; writing—review and editing, C.S.H., G.H., E.G., S.G., A.G.-B., M.F. and L.D.; visualization, C.S.H.; supervision, B.B., E.O. and A.G.-B. All authors have read and agreed to the published version of the manuscript.

Funding: This project was supported by the Regional Council of Reunion Island and by the TASC-MAR project, which is funded by the European Union under grant agreement number 634674.

Institutional Review Board Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the main text and the supplementary material of this article. 1D and 2D NMR raw data of compounds 1–4 are made freely available at https://doi.org/10.5281/zenodo.6301017.

Acknowledgments: The authors acknowledge the contribution of Crelux GmbH, Am Klopferspitz 19a, 82152 Martinsried, Germany for bioassays (CDK7, FynB and proteasome) methodology and validation.

Conflicts of Interest: The authors declare no conflict of interest.

Mar. Drugs **2022**, 20, 186 16 of 17

References

 Mehbub, M.F.; Lei, J.; Franco, C.; Zhang, W. Marine Sponge Derived Natural Products between 2001 and 2010: Trends and Opportunities for Discovery of Bioactives. *Mar. Drugs* 2014, 12, 4539–4577. [CrossRef] [PubMed]

- 2. Myers, N.; Mittermeier, R.A.; Mittermeier, C.G.; da Fonseca, G.A.B.; Kent, J. Biodiversity Hotspots for Conservation Priorities. *Nature* **2000**, 403, 853–858. [CrossRef] [PubMed]
- 3. Pettit, G.R.; Tan, R.; Gao, F.; Williams, M.D.; Doubek, D.L.; Boyd, M.R.; Schmidt, J.M.; Chapuis, J.C.; Hamel, E. Isolation and Structure of Halistatin 1 from the Eastern Indian Ocean Marine Sponge *Phakellia carteri*. *J. Org. Chem.* **1993**, *58*, 2538–2543. [CrossRef]
- 4. Samy, M.N.; Le Goff, G.; Lopes, P.; Georgousaki, K.; Gumeni, S.; Almeida, C.; González, I.; Genilloud, O.; Trougakos, I.; Fokialakis, N.; et al. Osmanicin, a Polyketide Alkaloid Isolated from *Streptomyces osmaniensis* CA-244599 Inhibits Elastase in Human Fibroblasts. *Molecules* **2019**, 24, 2239. [CrossRef]
- 5. Campos, P.-E.; Herbette, G.; Chendo, C.; Clerc, P.; Tintillier, F.; de Voogd, N.J.; Papanagnou, E.-D.; Trougakos, I.P.; Jerabek, M.; Bignon, J.; et al. Osirisynes G-I, New Long-Chain Highly Oxygenated Polyacetylenes from the Mayotte Marine Sponge *Haliclona* sp. *Mar. Drugs* **2020**, *18*, 350. [CrossRef]
- 6. Morrow, C.; Cárdenas, P. Proposal for a Revised Classification of the Demospongiae (Porifera). Front. Zool. 2015, 12, 7. [CrossRef]
- 7. Nygaard, H.B.; van Dyck, C.H.; Strittmatter, S.M. Fyn Kinase Inhibition as a Novel Therapy for Alzheimer's Disease. *Alzheimer's Res. Ther.* **2014**, *6*, 8. [CrossRef]
- 8. Kaufman, A.C.; Salazar, S.V.; Haas, L.T.; Yang, J.; Kostylev, M.A.; Jeng, A.T.; Robinson, S.A.; Gunther, E.C.; van Dyck, C.H.; Nygaard, H.B.; et al. Fyn Inhibition Rescues Established Memory and Synapse Loss in Alzheimer Mice: Fyn Inhibition by AZD0530. *Ann. Neurol.* **2015**, 77, 953–971. [CrossRef]
- 9. Tsuji, N.; Moriwaki, S.; Suzuki, Y.; Takema, Y.; Imokawa, G. The Role of Elastases Secreted by Fibroblasts in Wrinkle Formation: Implication through Selective Inhibition of Elastase Activity. *Photochem. Photobiol.* **2001**, 74, 283–290. [CrossRef]
- 10. Cardellina, J.H.; Graden, C.J.; Greer, B.J.; Kern, J.R. 17Z-Tetracosenyl 1-Glycerol Ether from the Sponges *Cinachyra alloclada* and *Ulosa ruetzleri*. *Lipids* 1983, 18, 107–110. [CrossRef]
- 11. Cardellina, J.H.; Nigh, D.; VanWagenen, B.C. Plant Growth Regulatory Indoles from the Sponges *Dysidea etheria* and *Ulosa ruetzleri*. *J. Nat. Prod.* **1986**, 49, 1065–1067. [CrossRef]
- 12. VanWagenen, B.C.; Larsen, R.; Cardellina, J.H.; Randazzo, D.; Lidert, Z.C.; Swithenbank, C. Ulosantoin, a Potent Insecticide from the Sponge *Ulosa ruetzleri*. *J. Org. Chem.* **1993**, *58*, 335–337. [CrossRef]
- 13. Prado, M.P.; Torres, Y.R.; Berlinck, R.G.S.; Desiderá, C.; Sanchez, M.A.; Craveiro, M.V.; Hajdu, E.; da Rocha, R.M.; Machado-Santelli, G.M. Effects of Marine Organisms Extracts on Microtubule Integrity and Cell Cycle Progression in Cultured Cells. *J. Exp. Mar. Biol. Ecol.* **2004**, *313*, 125–137. [CrossRef]
- 14. Galeano, E.; Martínez, A. Antimicrobial Activity of Marine Sponges from Urabá Gulf, Colombian Caribbean Region. *J. Mycol. Méd.* **2007**, *17*, 21–24. [CrossRef]
- 15. Biegelmeyer, R.; Schröder, R.; Rambo, D.F.; Dresch, R.R.; Stout, E.P.; Carraro, J.L.F.; Mothes, B.; Moreira, J.C.F.; Molinski, T.F.; da Frota Junior, M.L.C.; et al. Cytotoxic Effects on Tumour Cell Lines of Fatty Acids from the Marine Sponge *Scopalina ruetzleri*. *J. Pharm. Pharmacol.* **2015**, *67*, 746–753. [CrossRef]
- 16. Helber, S.B.; Hoeijmakers, D.J.J.; Muhando, C.A.; Rohde, S.; Schupp, P.J. Sponge Chemical Defenses Are a Possible Mechanism for Increasing Sponge Abundance on Reefs in Zanzibar. *PLoS ONE* **2018**, *13*, e0197617. [CrossRef]
- 17. Alvarez, B.; Hooper, J.N. Taxonomic Revision of the Order Halichondrida (Porifera: Demospongiae) of Northern Australia. Family Halichondriidae. *Beagle Rec. Mus. Art Galleries North. Territ.* **2011**, 27, 55–84. [CrossRef]
- 18. Lim, S.-C.; de Voogd, N.J.; Tan, K.-S. Biodiversity of Shallow-Water Sponges (Porifera) in Singapore and Description of a New Species of *Forcepia* (Poecilosclerida: Coelosphaeridae). *Contrib. Zool.* **2012**, *81*, 55–71. [CrossRef]
- 19. Shin, B.A.; Kim, Y.R.; Lee, I.-S.; Sung, C.K.; Hong, J.; Sim, C.J.; Im, K.S.; Jung, J.H. Lyso-PAF Analogues and Lysophosphatidyl-cholines from the Marine Sponge *Spirastrella abata* as Inhibitors of Cholesterol Biosynthesis. *J. Nat. Prod.* **1999**, *62*, 1554–1557. [CrossRef]
- 20. Nishikawa, Y.; Furukawa, A.; Shiga, I.; Muroi, Y.; Ishii, T.; Hongo, Y.; Takahashi, S.; Sugawara, T.; Koshino, H.; Ohnishi, M. Cytoprotective Effects of Lysophospholipids from Sea Cucumber *Holothuria atra*. *PLoS ONE* **2015**, *10*, e0135701. [CrossRef]
- 21. Do, M.N.; Erickson, K.L. Branched Chain Mono-Glycerol Ethers from a Taiwanese Marine Sponge of the Genus *Aaptos*. *Tetrahedron Lett.* **1983**, 24, 5699–5702. [CrossRef]
- 22. Quijano, L.; Cruz, F.; Navarrete, I.; Gómez, P.; Rios, T. Alkyl Glycerol Monoethers in the Marine Sponge *Desmapsamma anchorata*. *Lipids* **1994**, 29, 731–734. [CrossRef] [PubMed]
- 23. Sera, Y.; Adachi, K.; Shizuri, Y. A New Epidioxy Sterol as an Antifouling Substance from a Palauan Marine Sponge, *Lendenfeldia chondrodes*. *J. Nat. Prod.* **1999**, *62*, 152–154. [CrossRef] [PubMed]
- 24. Gunatilaka, A.A.L.; Gopichand, Y.; Schmitz, F.J.; Djerassi, C. Minor and Trace Sterols in Marine Invertebrates. 26. Isolation and Structure Elucidation of Nine New 5.Alpha.,8.Alpha.-Epidoxy Sterols from Four Marine Organisms. *J. Org. Chem.* 1981, 46, 3860–3866. [CrossRef]
- 25. Stark, T.; Hofmann, T. Structures, Sensory Activity, and Dose/Response Functions of 2,5-Diketopiperazines in Roasted Cocoa Nibs (Theobroma Cacao). *J. Agric. Food Chem.* **2005**, *53*, 7222–7231. [CrossRef]

Mar. Drugs **2022**, 20, 186 17 of 17

26. Li, X.; Dobretsov, S.; Xu, Y.; Xiao, X.; Hung, O.S.; Qian, P. Antifouling Diketopiperazines Produced by a Deep-Sea Bacterium, *Streptomyces fungicidicus. Biofouling* **2006**, 22, 187–194. [CrossRef]

- 27. Cabrera, G.M.; Butler, M.; Rodriguez, M.A.; Godeas, A.; Haddad, R.; Eberlin, M.N. A Sorbicillinoid Urea from an Intertidal *Paecilomyces marquandii. J. Nat. Prod.* **2006**, *69*, 1806–1808. [CrossRef]
- 28. Lee, J.; Wang, W.; Hong, J.; Lee, C.-O.; Shin, S.; Im, K.S.; Jung, J.H. A New 2,3-Dimethyl Butenolide from the Brittle Star *Ophiomastix mixta*. *Chem. Pharm. Bull.* **2007**, *55*, 459–461. [CrossRef]
- 29. Shi, H.; Yu, S.; Liu, D.; van Ofwegen, L.; Proksch, P.; Lin, W. Sinularones A-I, New Cyclopentenone and Butenolide Derivatives from a Marine Soft Coral *Sinularia* sp. and Their Antifouling Activity. *Mar. Drugs* **2012**, *10*, 1331–1344. [CrossRef]
- 30. Li, D.; Yang, Y.; Zhang, B.; Liao, X.; Jiang, Z.; Xu, S.; Zhao, B. Three New Butenolides from the Green Alga *Caulerpa racemosa* var. *turbinata*. *Chem. Biodivers*. **2020**, 17, e2000022. [CrossRef]
- 31. Colsch, B.; Fenaille, F.; Warnet, A.; Junot, C.; Tabet, J.-C. Mechanisms Governing the Fragmentation of Glycerophospholipids Containing Choline and Ethanolamine Polar Head Groups. *Eur. J. Mass Spectrom.* **2017**, 23, 427–444. [CrossRef] [PubMed]
- 32. Wang, M.; Carver, J.J.; Phelan, V.V.; Sanchez, L.M.; Garg, N.; Peng, Y.; Nguyen, D.D.; Watrous, J.; Kapono, C.A.; Luzzatto-Knaan, T.; et al. Sharing and Community Curation of Mass Spectrometry Data with Global Natural Products Social Molecular Networking. *Nat. Biotechnol.* **2016**, *34*, 828–837. [CrossRef] [PubMed]
- 33. Takano, E. Gamma-Butyrolactones: *Streptomyces* Signalling Molecules Regulating Antibiotic Production and Differentiation. *Curr. Opin. Microbiol.* **2006**, *9*, 287–294. [CrossRef] [PubMed]
- Joo, H.-S.; Yang, Y.-H.; Lee, C.-S.; Kim, J.-H.; Kim, B.-G. Fragmentation Study on Butanolides with Tandem Mass Spectrometry and Its Application for the Screening of ScbR-Captured Quorum Sensing Molecules in Streptomyces coelicolor A3(2). Rapid Commun. Mass Spectrom. 2007, 21, 764–770. [CrossRef]
- 35. Peng, J.; Li, J.; Hamann, M.T. The Marine Bromotyrosine Derivatives. Alkaloids Chem. Biol. 2005, 61, 59–262.
- 36. Moodie, L.W.K.; Žužek, M.C.; Frangež, R.; Andersen, J.H.; Hansen, E.; Olsen, E.K.; Cergolj, M.; Sepčić, K.; Hansen, K.Ø.; Svenson, J. Synthetic Analogs of Stryphnusin Isolated from the Marine Sponge *Stryphnus fortis* Inhibit Acetylcholinesterase with No Effect on Muscle Function or Neuromuscular Transmission. *Org. Biomol. Chem.* **2016**, *14*, 11220–11229. [CrossRef]
- 37. Lindsay, B.S.; Battershill, C.N.; Copp, B.R. Isolation of 2-(3'-Bromo-4'-Hydroxyphenol)Ethanamine from the New Zealand Ascidian *Cnemidocarpa bicornuta*. *J. Nat. Prod.* **1998**, *61*, 857–858. [CrossRef]
- 38. Aiello, A.; Fattorusso, E.; Imperatore, C.; Menna, M.; Müller, W.E.G. Iodocionin, a Cytotoxic Iodinated Metabolite from the Mediterranean Ascidian *Ciona ddwardsii*. Mar. Drugs **2010**, *8*, 285–291. [CrossRef]
- 39. Nicacio, K.J.; Ióca, L.P.; Fróes, A.M.; Leomil, L.; Appolinario, L.R.; Thompson, C.C.; Thompson, F.L.; Ferreira, A.G.; Williams, D.E.; Andersen, R.J.; et al. Cultures of the Marine Bacterium *Pseudovibrio denitrificans* Ab134 Produce Bromotyrosine-Derived Alkaloids Previously Only Isolated from Marine Sponges. *J. Nat. Prod.* 2017, 80, 235–240. [CrossRef]
- 40. Müller, W.E.G.; Klemt, M.; Thakur, N.L.; Schröder, H.C.; Aiello, A.; D'Esposito, M.; Menna, M.; Fattorusso, E. Molecular/Chemical Ecology in Sponges: Evidence for an Adaptive Antibacterial Response in *Suberites domuncula*. *Mar. Biol.* **2004**, 144, 19–29. [CrossRef]
- 41. Andresen, T.L.; Jensen, S.S.; Madsen, R.; Jørgensen, K. Synthesis and Biological Activity of Anticancer Ether Lipids That Are Specifically Released by Phospholipase A2 in Tumor Tissue. *J. Med. Chem.* **2005**, *48*, 7305–7314. [CrossRef] [PubMed]
- 42. Han, A.-R.; Song, J.-I.; Jang, D.S.; Min, H.-Y.; Lee, S.K.; Seo, E.-K. Cytotoxic Constituents of the Octocoral *Dendronephthya gigantea*. *Arch. Pharm. Res.* **2005**, *28*, 290–293. [CrossRef]
- 43. Li, S.-Q.; Yang, Y.-B.; Yang, X.-Q.; Jiang, Y.; Li, Z.-J.; Li, X.-Z.; Chen, X.; Li, Q.-L.; Qin, S.-H.; Ding, Z.-T. Two New Cyclic Tetrapeptides of *Streptomyces rutgersensis* T009 Isolated from *Elaphodus davidianus* Excrement. *Helv. Chim. Acta* 2016, 99, 210–214. [CrossRef]
- 44. Guo, X.; Zheng, L.; Zhou, W.; Cui, Z.; Han, P.; Tian, L.; Wang, X. A Case Study on Chemical Defense Based on Quorum Sensing: Antibacterial Activity of Sponge-Associated Bacterium *Pseudoalteromonas* sp. NJ6-3-1 Induced by Quorum Sensing Mechanisms. *Ann. Microbiol.* **2011**, *61*, 247–255. [CrossRef]
- 45. Qian, L.; Zhang, M.; Wu, S.; Zhong, Y.; Van Tol, E.; Cai, W. Alkylglycerols Modulate the Proliferation and Differentiation of Non-Specific Agonist and Specific Antigen-Stimulated Splenic Lymphocytes. *PLoS ONE* **2014**, *9*, e96207. [CrossRef] [PubMed]
- 46. Díaz, Y.M.; Laverde, G.V.; Gamba, L.R.; Wandurraga, H.M.; Arévalo-Ferro, C.; Rodríguez, F.R.; Beltrán, C.D.; Hernández, L.C. Biofilm Inhibition Activity of Compounds Isolated from Two *Eunicea* Species Collected at the Caribbean Sea. *Rev. Bras. Farmacogn.* 2015, 25, 605–611. [CrossRef]
- 47. Said Hassane, C.; Fouillaud, M.; Le Goff, G.; Sklirou, A.D.; Boyer, J.B.; Trougakos, I.P.; Jerabek, M.; Bignon, J.; de Voogd, N.J.; Ouazzani, J.; et al. Microorganisms Associated with the Marine Sponge *Scopalina hapalia*: A Reservoir of Bioactive Molecules to Slow Down the Aging Process. *Microorganisms* 2020, 8, 1262. [CrossRef]